Related Experiment Video
Updated: Jun 2, 2026
Isolation of Culturable Yeasts and Molds from Soils to Investigate Fungal Population Structure
Published on: May 27, 2022
Managing Azole Resistance in Aspergillus
Hisako Kushima1,2, Hiroshi Ishii2
1Department of Infection Control and Prevention, Fukuoka University Chikushi Hospital.
Abstract:
Azole antifungals are the cornerstone of therapy for aspergillosis, yet the global rise in azole-resistant Aspergillus fumigatus has become a major clinical concern. Resistance rates vary widely across regions, with particularly serious implications for chronic pulmonary aspergillosis (CPA), which requires long-term azole therapy. Resistance mechanisms largely involve cyp51A mutations, although additional genetic alterations and environmental factors, such as agricultural azole use, also play important roles. Cross-resistance among azoles is frequent, leaving clinicians with limited alternatives, such as liposomal amphotericin B or echinocandins, which are constrained by toxicity, fungistatic activity, and intravenous administration. Currently, antifungal susceptibility testing for filamentous fungi remains technically demanding and is not routinely available in many countries, including Japan, further complicating its management. Emerging approaches include the development of novel antifungal compounds and optimization of existing drugs through inhaled or nanoformulated delivery systems. Furthermore, fungal vaccines are attracting increasing attention as promising long-term solutions to stagnant antifungal pipelines and the growing challenge of drug resistance.
Insights
Azole resistance in Aspergillus fumigatus is a growing global concern, especially for chronic pulmonary aspergillosis. New antifungal strategies and diagnostics are urgently needed to combat this challenge.
Area of Science:
- Medical Mycology
- Antimicrobial Resistance
- Infectious Diseases
Background:
- Azole antifungals are primary treatments for aspergillosis.
- Rising azole resistance in Aspergillus fumigatus poses a significant clinical threat.
- Chronic pulmonary aspergillosis (CPA) necessitates long-term azole use, exacerbating resistance issues.
Purpose of the Study:
- To review the current landscape of azole resistance in Aspergillus fumigatus.
- To discuss the implications of resistance for aspergillosis treatment.
- To explore emerging strategies for managing azole-resistant fungal infections.
Main Methods:
- Literature review of azole resistance mechanisms in Aspergillus.
- Analysis of clinical implications and treatment challenges.
- Evaluation of current and novel antifungal approaches.
Main Results:
- Azole resistance is driven primarily by cyp51A mutations and influenced by agricultural azole use.
- Cross-resistance limits therapeutic options, with alternatives like amphotericin B and echinocandins having drawbacks.
- Antifungal susceptibility testing for fungi is complex and not widely available, hindering management.
Conclusions:
- Azole resistance in Aspergillus fumigatus requires urgent attention and innovative solutions.
- Development of novel antifungals, optimized drug delivery, and antifungal vaccines are crucial.
- Improved diagnostics and global surveillance are essential for effective management of resistant fungal infections.
More Related Videos
09:21Inhibition of Aspergillus flavus Growth and Aflatoxin Production in Transgenic Maize Expressing the α-amylase Inhibitor from Lablab purpureus L.
Published on: February 15, 2019
09:52Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
Published on: March 9, 2018
Related Concept Videos
01:15Antifungal Agents
01:28Fungal Phylum Ascomycota
01:25Mechanism of Antibiotic Resistance in MRSA
01:30Development of Antibiotic Resistance